Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED Funds to be used to optimize a formulation and demonstrate comparable efficacy to oral Viagra GREENVILLE, SC, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod®...

Zylö’s Erectile Dysfunction Product Concept Wins Best Abstract Award The product concept uses patent-pending Z-pods™ to sustainably—for over an hour—release nitric oxide GREENVILLE, SC, Nov. 10, 2021 (GLOBE NEWSWIRE) -- A novel nitric-oxide-releasing product concept...

Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials Funds to be used for scale-up, implementation of cGMP quality system, and pre-IND FDA meeting GREENVILLE, SC, July 20, 2021 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the...